3 completed, 3 terminated, 1 active not recruiting, 1 recruiting. 6 Phase 2, 1 Early Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 6 | Completed 2, Terminated 2, Active not recruiting 1, Recruiting 1 |
| Early Phase 1 | 1 | Terminated 1 |
| Phase 3 | 1 | Completed 1 |
Follow Relapsed T-Cell Lymphoma: new trials by email Literature Review of Relapsed T-Cell Lymphoma trials Research Report on Relapsed T-Cell Lymphoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Allo HSCT Using RIC and PTCy for Hematological Diseases Peripheral Blood Stem Cell Transplant, Allopurinol 300 MG, Fludarabine - Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia | Phase 2 | Recruiting | Masonic Cancer Center, University of Minnesota | 56 | 2023-05-01 | 2026-07-06 |
| CPI-613 in Combination With Bendamustine in Patients With Relapsed/Refractory T-Cell Non-Hodgkin Lymphoma CPI 613, Bendamustine - Relapsed T-Cell Lymphoma, Refractory T-Cell Lymphoma | Phase 2 | Terminated | Wake Forest University Health Sciences | 6 | 2020-09-16 | 2025-05-02 |
| Daratumumab Plus Gemcitabine, Dexamethasone, Cisplatin in pt R/R CD38+ PTCL-NOS, AITL and TFH Daratumumab - Refractory T-Cell Lymphoma, Relapsed T-Cell Lymphoma | Phase 2 | Terminated | Fondazione Italiana Linfomi - ETS | 8 | 2020-09-03 | 2025-03-28 |
| Reduced Intensity Flu/Mel/TBI Conditioning for HAPLO HCT Patients With Hematologic Malignancies Fludarabine, Melphalan, Total Body Irradiation - Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia | Phase 2 | Completed | H. Lee Moffitt Cancer Center and Research Institute | 34 | 2019-12-06 | 2025-12-11 |
| Trial Evaluating MGTA-456 in Patients With High-Risk Malignancy Fludarabine (FLU), Cyclophosphamide (CY), Total Body Irradiation (TBI) - Acute Myeloid Leukemia, Acute Lymphocytic Leukemia | Phase 2 | Active not recruiting | Masonic Cancer Center, University of Minnesota | 22 | 2019-01-02 | 2026-01-06 |
| UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep Fludarabine, Cyclophosphamide, MMF - Acute Leukemia, Acute Myeloid Leukemia | Phase 2 | Completed | Masonic Cancer Center, University of Minnesota | 15 | 2017-05-15 | 2025-07-04 |
| A Single Arm Study Evaluating the Efficacy and Safety of Pralatrexate in Subjects With Relapsed or Refractory PTCL pralatrexate, Vitamin B12 and folic acid - Refractory Peripheral T-Cell Lymphoma, Relapsed T-Cell Lymphoma | Phase 3 | Completed | Mundipharma (China) Pharmaceutical Co. Ltd | 85 | 2015-09-10 | 2019-10-01 |
| A Pilot Study of Oncaspar® + Dexamethasone in Patients With Relapsed or Refractory T-Cell Lymphoma PEG-L-asparaginase, Dexamethasone acetate - T-Cell Lymphoma, Relapsed T-Cell Lymphoma | Early Phase 1 | Terminated | Dana-Farber Cancer Institute | 2 | 2013-07-01 | 2017-03-06 |
Lymphoma, T-Cell (8) · Burkitt Lymphoma (4) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (4) · Leukemia, Myeloid, Acute (4) · Lymphoma, B-Cell, Marginal Zone (4) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (4) · Dendritic Cell Sarcoma, Interdigitating (3) · Hodgkin Disease (3) · Leukemia, Lymphocytic, Chronic, B-Cell (3) · Leukemia, Prolymphocytic (3) · Lymphoma, Follicular (3) · Lymphoma, Mantle-Cell (3) · Myelodysplastic Syndromes (3) · Myeloproliferative Disorders (3) · Leukemia, Biphenotypic, Acute (2)
Hemic and Lymphatic Diseases (8) · Immune System Diseases (8) · Immunoproliferative Disorders (8) · Lymphatic Diseases (8) · Lymphoma (8) · Lymphoproliferative Disorders (8) · Neoplasms (8) · Neoplasms by Histologic Type (8) · Lymphoma, Non-Hodgkin (7) · Bone Marrow Diseases (4) · Chronic Disease (4) · DNA Virus Infections (4) · Disease Attributes (4) · Epstein-Barr Virus Infections (4) · Hematologic Diseases (4)
Whole-Body Irradiation (4) · fludarabine (4) · Cyclophosphamide (3) · Mycophenolic Acid (3) · Melphalan (2) · Sirolimus (2) · fludarabine phosphate (2) · 10-propargyl-10-deazaaminopterin (1) · Allopurinol (1) · Antilymphocyte Serum (1) · Bendamustine Hydrochloride (1) · Busulfan (1) · Folic Acid (1) · Granulocyte Colony-Stimulating Factor (1) · Peripheral Blood Stem Cell Transplantation (1)
Masonic Cancer Center, University of Minnesota (3) · Dana-Farber Cancer Institute (1) · Fondazione Italiana Linfomi - ETS (1) · H. Lee Moffitt Cancer Center and Research Institute (1) · Mundipharma (China) Pharmaceutical Co. Ltd (1) · Wake Forest University Health Sciences (1)
United States (6) · China (1) · Italy (1)
Francesco Zaja (1) · Margaret MacMillan, MD, MSC (1) · Mark Juckett (1) · Nelli Bejanyan, MD (1) · Phillippe Armand, MD (1) · Rakhee Vaidya, M.B.B.S. (1) · Victoria YU (1)
P30CA012197 (1)